Daré Bioscience raises $6M to fund women's health pipeline
What's the deal? Daré Bioscience, a San Diego biotech focused on women's health, has priced a $6.0 million registered direct offering, it announced August 14, 2026. The Nasdaq-listed company will sell 4,379,581 shares (or pre-funded warrants) at $1.37 each to institutional investors.
The mechanics: The deal is priced at-the-market under Nasdaq rules. In a concurrent private placement, investors will also receive Series A and Series B warrants — each covering up to 4,379,581 additional shares — exercisable only after stockholder approval.
Who's involved? Ladenburg Thalmann & Co.Dealroom has a profile for this one. Try Dealroom → is acting as exclusive placement agent. The $6.0 million in gross proceeds are expected before placement fees and offering expenses.
Why now? The company describes itself as focused on closing the gap in women's health "between promising science and real-world solutions." The raise gives Daré fresh capital as it advances that work. Closing is expected on or about August 17, 2026, subject to customary conditions.
The signal: For a small-cap biotech, an at-the-market registered direct offering paired with warrant coverage is a familiar route to non-dilutive-adjacent capital without a traditional public raise. The warrant structure hands Daré potential future funding — if shares climb and stockholders approve — while giving it working capital now.
Read more: Stockwatch
Image credit: Generated with Gemini
